Want to see HK:9885 full AI Analyst Report?
Top Page
YSB Inc.
(9885)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$4.00
▲(9.59% Upside)
Action:Reiterated
Date:07/15/26
The score is driven primarily by improving financial performance—profitability returning in 2025 and consistently positive, growing free cash flow—tempered by higher leverage and very thin margins. Technicals are a meaningful drag due to a sustained downtrend versus key moving averages, while reasonable valuation and a solid dividend yield provide partial support.
Positive Factors
Strong cash generation
Consistently positive operating and free cash flow through 2022–2025, with FCF rising ~27% in 2025, indicates durable internal funding. This supports reinvestment, dividends or debt reduction without relying on external capital, strengthening long-term financial resilience.
Negative Factors
Very thin margins
Gross margin near 11% and net margin below 1% are unusually low for a software application business, leaving minimal operating leverage. This makes profits highly sensitive to modest cost increases or pricing pressure and constrains capital for R&D or sales scale-ups.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistently positive operating and free cash flow through 2022–2025, with FCF rising ~27% in 2025, indicates durable internal funding. This supports reinvestment, dividends or debt reduction without relying on external capital, strengthening long-term financial resilience.
Read all positive factors
YSB Inc. (9885) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.38B
Dividend Yield3.59%
Average Volume (3M)700.11K
Price to Earnings (P/E)11.0
Beta (1Y)0.64
Revenue Growth16.99%
EPS Growth126.15%
CountryHK
Employees6,950
SectorHealthcare
Sector Strength45
IndustrySoftware - Application
Share Statistics
EPS (TTM)0.22
Shares Outstanding692,487,300
10 Day Avg. Volume447,560
30 Day Avg. Volume700,110
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.37
Price to Sales (P/S)0.16
P/FCF Ratio5.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)HK$23.42B
YSB Inc. Business Overview & Revenue Model
Company Description
YSB Inc. provides a comprehensive digital platform tailored for the Chinese pharmaceutical sector, supporting a wide array of stakeholders such as drug companies, distributors, vendors, pharmacies, and primary healthcare facilities. Its key offeri...
YSB Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
49
Neutral
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.97B | 17.90B | 16.97B | 14.27B | 10.09B |
| Gross Profit | 2.31B | 1.81B | 1.74B | 1.43B | 913.83M |
| EBITDA | 133.97M | -42.13M | -3.07B | -1.35B | -392.32M |
| Net Income | 152.97M | 30.01M | -3.21B | -1.50B | -501.62M |
Balance Sheet | |||||
| Total Assets | 7.57B | 6.50B | 5.21B | 4.11B | 3.44B |
| Cash, Cash Equivalents and Short-Term Investments | 3.38B | 1.99B | 1.83B | 1.87B | 1.14B |
| Total Debt | 2.77B | 233.51M | 209.66M | 180.55M | 181.73M |
| Total Liabilities | 5.18B | 4.23B | 3.33B | 8.48B | 6.35B |
| Stockholders Equity | 2.44B | 2.32B | 1.92B | -4.35B | -2.90B |
Cash Flow | |||||
| Free Cash Flow | 619.46M | 632.46M | 433.65M | 54.49M | -608.06M |
| Operating Cash Flow | 637.70M | 655.86M | 451.20M | 98.20M | -487.09M |
| Investing Cash Flow | -896.27M | -253.58M | -792.95M | 41.07M | -352.80M |
| Financing Cash Flow | -70.97M | -109.81M | 255.34M | 261.93M | 1.12B |
YSB Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$1.45B | 13.60 | 9.51% | 10.04% | 21.19% | 19.81% | |
65 Neutral | HK$26.55B | 93.13 | 3.02% | 0.10% | 16.98% | ― | |
64 Neutral | HK$4.43B | -42.02 | -6.21% | ― | -3.42% | -13.93% | |
59 Neutral | HK$2.38B | 11.02 | 7.63% | 3.59% | 16.99% | 126.15% | |
56 Neutral | HK$1.77B | 22.50 | 13.67% | ― | 8.65% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$3.40B | -7.99 | -13.18% | ― | 40.17% | 76.39% |
* Healthcare Sector Average
HK:9885
YSB Inc.
3.50
-5.50
-61.10%
HK:8083
China Youzan
1.16
-1.92
-62.34%
HK:0268
Kingdee International Software Group Co
7.52
-8.75
-53.78%
HK:2013
Weimob
0.82
-1.57
-65.69%
HK:1588
Chanjet Information Technology Co., Ltd. Class H
4.46
-2.48
-35.73%
HK:6657
Baiwang Co., Ltd. Class H
11.66
-6.34
-35.22%
YSB Inc. Corporate Events
YSB Inc. Wins Extended Waiver for Joint Company Secretary Qualification
Jun 26, 2026
YSB Inc. has secured an extension from the Hong Kong Stock Exchange to continue a waiver related to the qualification requirements for its joint company secretary, Mr. Fei Chen, who also serves as executive director and chief financial officer. Al...
YSB Inc. Shareholders Back Dividend, Board and Capital Mandates at AGM
May 21, 2026
YSB Inc. said shareholders at its 21 May 2026 annual general meeting approved all resolutions, including the adoption of the 2025 audited accounts and a final dividend of RMB0.110 per share, signaling broad support for the company’s financia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.